Single-Use Bioreactors Market Size & Opportunities Analysis - Growth Strategies, Competitiveness, and Forecasts (2025 - 2032)

Single-Use Bioreactors Market Emerging Trends & Growth Drivers

Technological Advancements in Single-Use Bioreactor Design Are Key Trend

• The continuous innovations in the single-use bioreactor technology are a key trend addressing previous limitations and expanding their applicability to larger-scale production.
• Modern single-use bioreactors incorporate advanced sensor technologies, improved mixing mechanisms, and enhanced oxygen transfer capabilities that match or exceed the performance of traditional stainless-steel systems.
• The development of single-use bioreactors with capacities exceeding 2,000 liters has enabled their adoption for commercial-scale production of established biopharmaceutical products.
• The advances in material science have improved the robustness and reliability of single-use bioreactor components.
• New polymer films demonstrate enhanced mechanical strength, reduced extractables and leachables profiles, and improved gas barrier properties.
• The American Society for Testing and Materials has established comprehensive standards for single-use system qualification, providing manufacturers and users with standardized testing protocols that ensure product quality and patient safety.
• Integration of digital technologies and process analytical tools has transformed single-use bioreactors into sophisticated bioprocessing platforms.
• Real-time monitoring capabilities, automated process control, and data analytics integration enable precise process optimization and consistent product quality.
• These technological enhancements have expanded single-use bioreactor applications beyond traditional monoclonal antibody production to include complex molecules such as viral vectors, exosomes, and cell therapies, driving market growth across diverse therapeutic areas.
• Regulatory bodies, such as the FDA and EMA, encourage the adoption of single-use technologies, offering guidance that supports flexible manufacturing and contamination control.

Growing Demand for Biopharmaceuticals Are Biggest Driver

• The pharmaceutical industry's increasing focus on biologics development represents a fundamental driver for the single-use bioreactor market.
• Single-use systems are used at clinical size for over 80% of bioprocessing operations and will continue to be used by biomanufacturers and CMOs on a larger commercial scale.”
• In 2023, the U.S. FDA approved 55 new biologics, which was an around 49% increase from the 37 approvals in 2022.
• Furthermore, many biopharmaceutical, biotechnological, and pharmaceutical firms are dealing with an immense amount of cost and time pressure in the production of therapeutics.
• Single-use bioreactors offer distinct advantages for biologics production, particularly in terms of operational flexibility and reduced contamination risks.
• These systems enable manufacturers to quickly switch between different products without extensive cleaning and validation procedures, reducing downtime from weeks to days.
• The cost-effectiveness of single-use bioreactors becomes particularly evident in clinical-stage production, where batch sizes are smaller and product changes are frequent.
• According to industry analysis, single-use systems can reduce overall production costs by 25–30% for clinical-scale manufacturing.
• A significant rise in the adoption of such bioreactors by startups and small & medium-sized enterprises has been observed.
• This economic benefit has prompted both contract manufacturing organizations and pharmaceutical companies to adopt single-use technologies as their primary production platform for early-stage development programs.
• Further, due to the flexibility offered by such systems, they are increasingly used by contract development and manufacturing organizations (CDMOs).
• Improved sensor technologies, such as Raman spectroscopy; and capacitance probes integrated into single-use systems enable better process monitoring and control and a higher product yield and quality.
• With perfusion culture and high-cell-density processes, single-use bioreactors are evolving to support more-intensive bioprocesses, enabling higher productivity per batch and meeting growing biopharmaceutical demand.

Single-Use Bioreactors Market Segmentation Analysis

Product Analysis

The systems category held the largest market share, of 80%, in 2024. This is attributable to the extensive utilization of such systems in biopharmaceutical manufacturing facilities requiring a high yield of products. Additionally, such systems are economical, versatile, and possess large-scale production capabilities. Moreover, there is a surging need for rapid development of biotherapeutics, such as antibodies, hormones, vaccines, and enzymes, in large quantities, which can be produced in such bioreactors.

Within the systems category, the 101-500 L capacity range represents the fastest-growing sub-segment, with pharmaceutical companies increasingly adopting these mid-scale systems for both clinical and early commercial production.

The media bags category will have the highest CAGR, of 22.1%, due to the expanding adoption of single-use technologies beyond the bioreactor vessel itself to encompass the entire bioprocessing workflow. Three-dimensional media bags, in particular, are gaining significant traction due to their superior mixing characteristics and reduced shear stress on sensitive cell cultures.

The products analyzed in this report are:

• Systems (Largest Category)
  • Up to 10 l
  • 11–100 l
  • 101–500 l
  • 501–1,500 l
  • Above 1,500 l
• Media Bags (Fastest-Growing Category)
  • 2D
  • 3D
• Assemblies

Type Analysis

The stirred-tank category held the larger market share, of 75%, in 2024. This is attributable to numerous advantages offered by them, such as low operating costs, good fluid mixing ability and oxygen transfer, and easy scale-up. Recent innovations in single-use stirred-tank design, including improved impeller configurations and enhanced oxygen transfer capabilities, have expanded their application range to include demanding processes such as microbial fermentation and high-titer monoclonal antibody production.

The wave-induced will have the higher CAGR, of 22.2%, due to the gentle mixing mechanism that provides optimal conditions for shear-sensitive cell cultures, particularly mammalian cells used in monoclonal antibody production. Furthermore, advantages like flexible configuration of accessories, convenient handling, low costs, and long-life cycle are posing a positive impact on the market in this category. The proven track record of wave-induced bioreactors in commercial biopharmaceutical production has established them as the preferred choice for many manufacturers.

The types analyzed in this report are:

• Wave-Induced (Faster-Growing Category)
• Stirred-Tank (Larger Category)

Cell Type Analysis

The mammalian cells category held the largest market share, of 65%, in 2024, because these cells are widely used for the development of recombinant proteins and biopharmaceutical therapies. According to a study, it has been observed that a large number of biopharmaceutical candidates are developed using mammalian cell culture. Chinese Hamster Ovary cells remain the workhorse of the industry, with over 70% of approved biopharmaceutical products manufactured using CHO cell lines. Single-use bioreactors provide ideal cultivation conditions for mammalian cells while eliminating cross-contamination risks between production campaigns.

The yeast cells category will have the highest CAGR, of 22.6%, because these cells offer advantages in the production of therapeutic recombinants and aid in serving as heterologous and homologous hosts for biopharmaceutical synthesis. Furthermore, advantages offered by them, such as easy gene manipulation, significant growth on affordable media, and ease of addition of post-translational alterations of eukaryotes, have gained the attention of several research organizations and researchers to utilize such cells in clinical settings.

Two yeast strains—Pichia pastoris and Saccharomyces cerevisiae—have gained prominence in recombinant protein production, especially vaccines and biosimilars, due to their scalability and ability to perform post-translational modifications. Moreover, Pichia pastoris is a low-cost medium, making it ideal for cost-sensitive biologics production in emerging markets.

The cell types analyzed in this report are:

• Mammalian Cells (Largest Category)
• Yeast Cells (Fastest-Growing Category)
• Bacterial Cells

Molecule Type Analysis

The vaccines category held the largest market share, of 30%, in 2024. This is attributed to the upsurge in infectious diseases over the last few years. The rise in contagious ailments has led to a surge in the mass production of vaccines for prophylaxis and therapeutic purposes. Additionally, the outbreak of the COVID-19 pandemic led many biopharmaceutical firms to manufacture vaccines rapidly and in large amounts. This led them to adopt single-use bioreactors, as they provide simple installation, require less capital investments, and eliminate validation issues and others. All these benefits offered by the system pose a positive impact on the single-use bioreactors market.

The gene-modified cells category will have the highest CAGR, of 22.4%. This can be attributed to the advancements in the field of genetics and genomics, and the surging adoption of cell and gene therapies for the treatment of several serious genetic disorders like sickle cell anemia, hemophilia, cystic fibrosis, and muscular dystrophy. Single-use bioreactors offer critical advantages for gene-modified cell production, including enhanced containment for viral vector manufacturing and the flexibility to accommodate patient-specific production runs.

The molecule types analyzed in this report are:

• Monoclonal Antibodies
• Gene-Modified Cells (Fastest-Growing Category)
• Vaccines (Largest Category)
• Stem Cells

Application Analysis

The research & development category held the largest market share, of 75%, in 2024, due to the extensive use of single-use systems in the preclinical and early clinical phases of biopharmaceutical development. These stages require high flexibility, quick turnaround times, and cost-effective solutions. Global biopharmaceutical R&D spending today ranges from USD 250 billion to USD 300 billion annually, with comprehensive estimates clustering near USD 276 billion.

The bioproduction category will have the highest CAGR, of 22.8%, due to the increasing adoption of single-use technologies for commercial-scale manufacturing of biopharmaceuticals. The proven reliability, regulatory acceptance, and economic advantages of single-use bioreactors have led to their widespread implementation in both clinical and commercial production facilities. Major biopharmaceutical companies have validated single-use systems for producing blockbuster biologics, demonstrating their capability to meet stringent quality requirements at commercial scales.

The applications analyzed in this report are:

• Research & Development (Largest Category)
• Process Development
• Bioproduction (Fastest-Growing Category)

Usage Type Analysis

The lab-scale production category held the largest market share, of 50%, in 2024, because the biopharmaceutical industry requires the frequent utilization of bioreactors for various clinical and preclinical research purposes.

The large-scale production category will have the highest CAGR, of 22.3%, due to the rising demand for biopharmaceutical commodities for commercial purposes and the increasing production capacities to meet these demands. The economic benefits of reduced facility infrastructure and operational flexibility continue to drive the adoption of single-use systems for large-scale production.

The usage types analyzed in this report are:

• Lab-Scale Production (Largest Category)
• Pilot-Scale Production
• Large-Scale Production (Fastest-Growing Category)

End User Analysis

The pharmaceutical & biotechnology companies category held the largest market share, of 60%, in 2024. These companies represent the primary consumers of single-use bioreactor technology, utilizing these systems across the entire product lifecycle from early research through commercial manufacturing. The strategic shift towards in-house manufacturing capabilities, particularly for cell and gene therapies, has driven increased investment in single-use bioprocessing infrastructure among pharmaceutical and biotechnology companies.

The CROs & CMOs category will have the highest CAGR, of 22.1%, driven by the biopharmaceutical industry's increasing reliance on outsourcing for both development and manufacturing activities. Single-use bioreactors enable CROs and CMOs to offer flexible, cost-effective services across multiple clients and products without cross-contamination concerns. The ability to rapidly reconfigure production facilities for different products makes single-use technology particularly attractive for contract service providers seeking to maximize facility utilization and minimize changeover times. The size of the CRO services market was USD 69.1 billion in 2024, and it is projected to expand by 12.8% from 2025 to 2032, ultimately reaching USD 179.2 billion by 2032.

The end users analyzed in this report are:

• CROs & CMOs (Fastest-Growing Category)
• Pharmaceutical & Biotechnology Companies (Largest Category)
• Academic & Research Institutions

Single-Use Bioreactors Market Regional Growth Dynamics

North America Single-Use Bioreactor Market Size

North America held the largest market share, of 35%, in 2024. This is credited to the growing prevalence of chronic ailments like diabetes, the presence of top players and robust healthcare facilities, technological advancements in this field, and robust research and development initiatives, such as availability and accessibility to research funding, in the region.

U.S. Single-Use Bioreactor Market Size

The U.S. market is dominant due to the growing adoption of cutting-edge technologies, the rising public awareness of disease prevention, strong government support, and advanced healthcare facilities in the country. The implementation of advanced manufacturing initiatives by the U.S. government has further accelerated single-use bioreactor adoption. The National Institute of Standards and Technology has established programs supporting biopharmaceutical manufacturing innovation.

Asia-Pacific Single-Use Bioreactor Market Size

Asia-Pacific will have the highest CAGR, of 23.4%, due to the expanding biopharmaceutical manufacturing capabilities, increasing government investments in biotechnology infrastructure, and the growing presence of global pharmaceutical companies establishing production facilities in Asian countries. The cost advantages of manufacturing in Asia Pacific, combined with improving regulatory frameworks and skilled workforce availability, have accelerated the adoption of advanced bioprocessing technologies, including single-use bioreactors. Moreover, Japan's aging population and strong demand for innovative biopharmaceuticals have driven significant investments in domestic manufacturing capabilities. Japanese pharmaceutical companies are increasingly partnering with global technology providers to establish state-of-the-art biomanufacturing facilities utilizing advanced single-use bioreactor platforms.

China Single-Use Bioreactor Market Size

China dominates the market due to the rising government's Made in China 2025 initiative, which specifically identifies biopharmaceuticals as a strategic industry, with substantial funding allocated for manufacturing technology upgrades. China has been actively upgrading and building new biopharmaceutical manufacturing facilities, most of which prioritize flexible single-use technologies over stainless steel systems due to cost, speed, and scalability.

The geographical breakdown of the market is as follows:

• North America (Largest Regional Market)
  • U.S. (Larger and Faster-Growing Country)
  • Canada
• Europe
  • Germany (Largest Country)
  • U.K. (Fastest-Growing Country)
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific (Fastest-Growing Regional Market)
  • China (Largest and Fastest-Growing Country)
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of APAC
• Latin America
  • Brazil (Largest Country)
  • Mexico (Fastest-Growing Country)
  • Rest of LATAM
• Middle East and Africa
  • Saudi Arabia (Largest Country)
  • South Africa
  • U.A.E. (Fastest-Growing Country)
  • Rest of MEA

Single-Use Bioreactors Market Competitive Landscape

The market is moderately fragmented due to the presence of large global players and several regional or niche companies. While top firms hold a significant share due to advanced technologies and strong partnerships, many smaller companies continue to compete by offering specialized solutions, regional support, and competitive pricing.

Single-Use Bioreactors Market News

• In April 2025, Thermo Fisher Scientific Inc. introduced the 5-l DynaDrive bench-scale single-use bioreactor. This supports seamless scale-up from 5 l to 5,000 l using consistent platform design and film materials, enhancing process development workflows.
• In March 2025, Sartorius AG announced its intention to invest in a new production line for pallet tanks, utilized in single-use bioreactors at its R&D facility in Bengaluru. The investment is planned to continue until 2027 in order to satisfy both local and global demands. Additionally, the company stated that it aims to double its annual capacity for the manufacturing and testing of chromatography systems by 2025.
• In August 2023, Sartorius AG and Repligen Corporation launched an integrated Biostat STR bioreactor system that embeds Repligen’s XCell ATF perfusion technology directly into the STR platform. This innovation simplifies upstream intensification with enhanced cell retention control and process automation for 50–2,000 l scales.